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No evidence so far on the protective effect of 
hydroxychloroquine to prevent COVID-19: 
comment by Joob and Wiwanitkit
We read with interest the comment by Joob and Wiwanitkit1 
on the letter published by Monti et al in the Annals of the 
Rheumatic Diseases (ARD).2 In it, the authors state that there 
are no reported cases of patients with systemic lupus erythe-
matosus (SLE) with COVID-19 and suggest that this may be 
due to a protective effect of hydroxychloroquine, a mainstay 
treatment taken by most patients with SLE. A similar sugges-
tion had already been made earlier this month in the ARD by 
colleagues from Italy,3 the first hardly- hit western country, and 
was reinforced by yet another recently published letter.4
As is now widely known, this old antimalarial drug, which 
has been part of the daily therapeutic armamentarium of 
rheumatologists for decades, has reached the global spotlight 
after demonstration of antiviral efficacy in vitro5 and some 
suggestions of clinical efficacy in studies with methodolog-
ical limitations and fast peer- review processes.6 The scientific 
discussion on the potential validity of these findings—which 
were to be confirmed—was seized by some politicians who 
quickly transformed it into a matter of belief and convic-
tion. Moreover, an additional problem was created in several 
countries, where a general run to antimalarials led to nation-
wide drug shortage and prevented patients with rheumatic 
diseases from accessing these critical drugs to control their 
disease.
The yearning for an effective treatment for COVID-19 
should not deter the scientific community from critically eval-
uating available evidence. Rather, it should make it raise the 
bar even higher to avoid that possible spurious findings are 
used in the wrong way.
In this regard, we would like to dispute both the statement 
and the suggestion by Joob and Wiwanitkit in their comment.1 
Indeed, the authors comment on the letter by Monti et al, who 
studied a cohort of 320 patients with rheumatoid arthritis (RA) 
or spondyloarthritis, but did not have a single patient with SLE.2 
Still, out of the eight patients who developed a clinical picture 
compatible with COVID-19, three were already on hydroxy-
chloroquine, making it confusing to suggest a protective effect 
of this drug. Recently, the COVID-19 Global Rheumatology 
Alliance launched a worldwide register for patients with rheu-
matic diseases with severe acute respiratory syndrome corona-
virus 2 (SARS- CoV-2) infection.7 In the initial report that was 
just published, 19 out of 110 patients had SLE, although no 
treatment/outcome details were provided specifically for these 
patients.8
Additionally, we report two cases of patients with SLE under 
long- term treatment with hydroxychloroquine, who devel-
oped COVID-19 (table 1). Both were young patients, with 
controlled disease activity prior to the infection. Both had 
confirmed close contacts with subjects later diagnosed with 
COVID-19, developed mild disease and fully recovered. While 
these two cases do not provide any definite answer to the ques-
tion of whether antimalarials can prevent COVID-19 or severe 
disease, they show that, indeed, patients with SLE can develop 
disease, even if on stable hydroxychloroquine therapy. The 
mild disease course should not be attributed to the concom-
itant antimalarial. Rather, it is likely related to other factors 
known to be associated with better outcomes, such as female 
sex and younger age.
In these agitated, confusing times, caution is warranted 
in interpreting the vast amount of information emerging on 
COVID-19. Until robust evidence is available, we should stick 
to what we know by now: antimalarials are crucial drugs for 
patients with SLE, RA and other rheumatic diseases, who also 
seem to be susceptible to infection by SARS- CoV-2. Whether 
they are effective drugs for the prevention or treatment of 
COVID-19 is yet an open avenue. One we should not rush into 
without decisive, firm steps.
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Table 1 Clinical features of two patients with SLE who developed 
COVID-19
Patient 1 Patient 2
Age 30 38
Sex Female Female
Disease duration 6.8 years 2.1 years
SLE clinical 
manifestations
Oral ulcers, photosensitivity, 
inflammatory arthralgia
Malar rash, photosensitivity, 
alopecia, fatigue, inflammatory 
arthralgia, Raynaud’s phenomenon
SLE- related laboratorial 
features
ANA (1/320), anti- Sm, anti- 
dsDNA, LAC
ANA (1/320), anti- Sm, anti- 
RNP, anti- Ro, anti- dsDNA, 
leucopenia, neutropenia, 
hypergammaglobulinaemia
Comorbidities Chronic urticaria Plaque morphea (childhood onset), 
hypothyroidism
Smoking status Non- smoker (ever) Non- smoker (ever)
csDMARDs, dose 
(duration)
HCQ, 400 mg/day (7 years) HCQ, 400 mg/day (2.8 years)
MTX, 15 mg/week (3.5 years)
Glucocorticoids, dose 
(duration)
No PDN, 5 mg/day (2.1 years)
NSAIDs No No
ACEi/ARB No No
SLEDAI (prior to 
COVID-19)
0 0
Epidemiological link Close contact with 
confirmed case (colleague)
Short close contact (30 min) with 
two subjects arriving from Madrid 
(Spain)
Time from contact to 
symptom onset
6 days 6 days




Time from symptom 
onset to first positive 
RT- PCR test
8 days 5 days
Hospitalisation No No
Antiviral treatment No No
Symptom duration 16 days 7 days
Time from symptom 
onset to two negative 
RT- PCR tests
26 days 28 days






Complete recovery Yes Yes
ACEi, angiotensin- converting enzyme inhibitor; ANA, antinuclear antibody; ARB, angiotensin- 
II receptor blocker; csDMARDs, conventional synthetic disease- modifying antirheumatic 
drugs; HCQ, hydroxychloroquine; LAC, lupus anticoagulant; MTX, methotrexate; NSAIDs, 
non- steroidal anti- inflammatory drugs; PDN, prednisolone; RNP, ribonucleoprotein; RT- PCR, 
reverse transcription polymerase chain reaction; SLE, systemic lupus erythematosus; SLEDAI, 
systemic lupus erythematosus disease activity index.
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